Correction
This article was originally published in The Tan Sheet
Executive Summary
The story included in the Feb. 5 issue covering Schering-Plough's fourth-quarter and full-years earnings reported the incorrect price of the Zegerid licensing deal full-year and earnings-per-share numbers. Schering-Plough paid $15 mil. for the licensing deal with Santarus for OTC Zegerid and full-year EPS for 2006 was 71 cents compared to 12 cents in 2005...